ArticleJournal of virology2002
Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 48 citations in OpenAlex.
- Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon.Cellular and molecular life sciences : CMLS · 2024Review
- Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.Microbiology spectrum · 2021Article
- Review
- Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders.NPJ vaccines · 2020Article
- Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates.Blood advances · 2019Article
- Roles of lipoprotein receptors in the entry of hepatitis C virus.World journal of hepatology · 2015Review
- The past, present and future of neutralizing antibodies for hepatitis C virus.Antiviral research · 2014Review
- Article
- A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81.PloS one · 2014Article
- Review
- Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes.Hepatology (Baltimore, Md.) · 2011Article
- Transcriptional repression of C4 complement by hepatitis C virus proteins.Journal of virology · 2011Article
- New antiviral therapies for chronic hepatitis C.Hepatology international · 2010Article
- Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.Protein & cell · 2010Article
- Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus.Cell host & microbe · 2009Article
- Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.Expert reviews in molecular medicine · 2008Review
- Antibody-dependent enhancement of hepatitis C virus infection.Journal of virology · 2008Article
- Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.Cell host & microbe · 2007Article
- Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins.Journal of virology · 2007Article
- Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells.Journal of virology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
We previously reported a number of features of hepatitis C virus (HCV) chimeric glycoproteins related to pseudotype virus entry into mammalian cells. In this study, pseudotype virus was neutralized by HCV E2 glycoprotein-specific antibodies and infected human sera. Neutralization (50% reduction of pseudotype virus plaque formation) was observed with two human immunoglobulin G1 monoclonal antibodies (MAbs) at concentrations of between 2.5 and 10 microg/ml. A hyperimmune rabbit antiserum to an E2 hypervariable region 1 (HVR1) mimotope also exhibited an HCV E2 pseudotype virus neutralization titer of approximately 1/50. An E1 pseudotype virus used as a negative control was not neutralized to a significant level (<1/10) by these MAbs or rabbit antiserum to E2 HVR1. Since HCV probably has a lipid envelope, the role of complement in antibody-mediated virus neutralization was examined. Significant increases in the neutralization titers of the human MAbs (approximately 60- to 160-fold higher) and rabbit antiserum to HVR1 mimotopes (approximately 10-fold higher) were observed upon addition of guinea pig complement. Further, these studies suggested that complement activation occurred primarily by the classical pathway, since a deficiency in the C4 component led to a significant decrease in the level of virus neutralization. This same decrease was not observed with factor B-deficient complement. We also determined that 9 of 56 HCV-infected patient sera (16%) had detectable pseudotype virus neutralization activity at serum dilutions of between 1/20 and 1/50 and that complement addition enhanced the neutralization activity of some of the HCV-infected human sera. Taken together, these results suggest that during infection, HCV E2 glycoprotein induces a weak neutralizing antibody response, that those antibodies can be measured in vitro by the surrogate pseudotype virus plaque reduction assay, and that neutralization function can be augmented by complement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.